David Nierengarten's guest appearances

David Nierengarten

OIS Podcast

Nick Curtis

Jay Cormier

Brent Saunders

Daniel Chao

David Muller

Andrew Chang

David Tanzer

Ken Mills

Bill Link

Patrick Mooney

Diana Driscoll

Brent Jones

Ponders IPO

Jay Duker

Steve Charles

OwlTail

Wedbush Dissects

Together, Roche and Biogen paid over $5.5 billion for gene therapy companies Spark and Nightstar. What does this mean for the emerging technology? Spark, of course, received FDA approval for Luxturna as a treatment for inherited retinal disease. But the drug isn’t Roche’s primary focus. Meanwhile, Nightstar’s clinical-stage products could give Biogen a second shot at a gene therapy portfolio after the company severed ties with AGTC in December. Could Biogen make a move to bulk up its ophthalmology offerings?  

<p>Together, Roche and Biogen paid over $5.5 billion for gene therapy companies Spark and Nightstar. What does this mean for the emerging technology? Spark, of course, received FDA approval for Luxturna as a treatment for inherited retinal disease. But the drug isn’t Roche’s primary focus. Meanwhile, Nightstar’s clinical-stage products could give Biogen a second shot at a gene therapy portfolio after the company severed ties with AGTC in December. Could Biogen make a move to bulk up its ophthalmology offerings?  </p>

Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree